Gilead Sciences, Inc. (NASDAQ:GILD) is among the Renaissance Technologies Portfolio: 10 Biggest Stocks. On September 16, JPMorgan analyst Chris Schott lifted the stock’s price target to $145 from $135 while maintaining an Overweight rating for its shares. JPMorgan Lifts Gilead Sciences, Inc. (GILD)'s Price Target To $145, Maintains Overweight Rating While the firm left most of its large-cap biopharma estimates unchanged, it adjusted share price targets on a move from December 2025 to December 2026. The ...

公司评级与目标价 - 对Gilead Sciences Inc (GILD) 初始评级为强烈买入 目标价181美元 [1] 公司业务领域 - 专注于HIV 病毒性肝炎 肿瘤学及其他未满足医疗需求领域的变革性疗法研发与商业化 [1] 研究机构方法论 - 采用结构化可重复框架 筛选具备持久商业模式 现金流潜力被错误定价及资本配置智慧的公司 [1] - 结合严谨基本面分析与高信号判断驱动流程 避免噪音叙事和过度复杂预测 [1] - 估值基于行业相关倍数 强调可比性 简洁性与相关性 [1] - 重点覆盖经历结构性变化或暂时错配的低估企业 通过冷静分析与差异认知获取不对称回报 [1]